Alex Thompson
Stock Analyst at Stifel
(4.66)
# 254
Out of 5,182 analysts
41
Total ratings
65.71%
Success rate
27.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Buy | $70 → $92 | $71.90 | +27.96% | 3 | Mar 18, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $47 → $72 | $76.39 | -5.75% | 2 | Mar 13, 2026 | |
| ANAB AnaptysBio | Maintains: Buy | $56 → $85 | $66.59 | +27.65% | 3 | Mar 5, 2026 | |
| CLDX Celldex Therapeutics | Reiterates: Buy | $58 → $68 | $33.66 | +102.02% | 1 | Feb 26, 2026 | |
| ALMS Alumis | Initiates: Buy | $44 | $24.75 | +77.78% | 1 | Feb 25, 2026 | |
| PALI Palisade Bio | Initiates: Buy | $5 | $1.96 | +155.10% | 1 | Feb 25, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $254 → $256 | $226.66 | +12.94% | 4 | Dec 11, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,028 → $1,248 | $783.74 | +59.24% | 5 | Dec 11, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $87.16 | -25.42% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $40.81 | -38.74% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $13.25 | +66.04% | 1 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $55 | $86.68 | -36.55% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $14.42 | +149.65% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $38.62 | +55.36% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $16.85 | +309.50% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $4.41 | -77.32% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $13.50 | +196.30% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $28.62 | +18.80% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.21 | +2,627.27% | 1 | Dec 14, 2022 |
Spyre Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $70 → $92
Current: $71.90
Upside: +27.96%
Oruka Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $47 → $72
Current: $76.39
Upside: -5.75%
AnaptysBio
Mar 5, 2026
Maintains: Buy
Price Target: $56 → $85
Current: $66.59
Upside: +27.65%
Celldex Therapeutics
Feb 26, 2026
Reiterates: Buy
Price Target: $58 → $68
Current: $33.66
Upside: +102.02%
Alumis
Feb 25, 2026
Initiates: Buy
Price Target: $44
Current: $24.75
Upside: +77.78%
Palisade Bio
Feb 25, 2026
Initiates: Buy
Price Target: $5
Current: $1.96
Upside: +155.10%
Ascendis Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $254 → $256
Current: $226.66
Upside: +12.94%
argenx SE
Dec 11, 2025
Maintains: Buy
Price Target: $1,028 → $1,248
Current: $783.74
Upside: +59.24%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $87.16
Upside: -25.42%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $40.81
Upside: -38.74%
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $13.25
Upside: +66.04%
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $86.68
Upside: -36.55%
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $14.42
Upside: +149.65%
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $38.62
Upside: +55.36%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $16.85
Upside: +309.50%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $4.41
Upside: -77.32%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $13.50
Upside: +196.30%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $28.62
Upside: +18.80%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.21
Upside: +2,627.27%